European operator of nursing homes, retirement residences, clinics and home-care services, formerly known as Korian.
European operator of nursing homes, retirement residences, clinics and home-care services, formerly known as Korian.
Earns daily charges from residents and from public payers such as national health insurers, with rates often set or capped by governments, so occupancy and staff costs decide results. France, Germany and the Benelux countries are its core markets, and it has been selling assets and cutting debt since renaming itself from Korian in 2023.
In one line: A European Brookdale Senior Living, spanning several countries.
Moat: narrow (regulatory licence, scale, installed base). Large multi-country bed network and licences, but reimbursement-dependent and highly leveraged like peers.
Headquarters: Puteaux, France · Founded: 2003 · Employees: 70,685
Size Clariane (CLARI.PA) is a France Health Care company (Medical/Nursing Services) with a market value of $1.32B, the 122nd largest of 206 France companies the cockpit tracks. Shares closed at €3.36 on 18 Nov 2026.
Performance Over six months the shares fell 20.1%, against +17.1% for the median peer and -2.1% for the France market (cap-weighted) — 3rd lowest of 21 in its peer set.
Growth Revenue grew 1.0% over the last twelve months (peer median +7.9%); the operating margin is 6.2% (peer median 4.8%).
Valuation It trades at 8.2× forward earnings against a peer median of 29.4× (2nd cheapest of 16).
Price implies For today's price to make sense, revenue must grow about 7% a year for seven years (Req g). Recent delivered growth is +7%, so the hurdle is +0 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 3.1 points below its cost of capital (5.3% WACC).
Credit Clariane has 6 bonds outstanding ($3.02B), rated B+ by the agencies and trading like B+ at a weighted spread of 377 bp.
Next results Next results expected around 26 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | €5.35B | €5.31B | €5.28B | €5.05B | €4.53B |
| Revenue growth | — | +1% | +5% | +11% | — |
| Gross profit | €736M | €628M | €644M | €383M | €351M |
| EBITDA | €1.03B | €1.01B | €1.01B | €1.02B | €1.00B |
| Net income | €12.6M | €1.59M | -€39.9M | -€105M | €22.1M |
| Free cash flow | €571M | €578M | €352M | €223M | €116M |
| Capital expenditure | €231M | €262M | €320M | €499M | €631M |
| Total debt | n/a | €7.81B | €7.98B | €8.55B | €8.27B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Clariane CLARI.PA | $1.32B | -20% | +1% | 6% | 8.2× | 6.8% |
| Emeis EMEIS.PA | $1.78B | -33% | +4% | 3% | n/a | 21.2% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | CLARI.PA | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +2.6% | -1.6% | 9th highest of 21 |
| 6-month return | -20.1% | +17.1% | 3rd lowest of 21 |
| Distance from 52-week high | -24.1% | -22.2% | 10th lowest of 21 |
| Revenue growth (TTM) | +1.0% | +7.9% | 8th lowest of 21 |
| Operating margin | 6.2% | 4.8% | 11th highest of 21 |
| Forward P/E | 8.2× | 29.4× | 2nd cheapest of 16 |
| Growth the price implies (Req g, 7 yrs) | 6.8% | 8.5% | 7th least demanding of 15 |
| Growth delivered (Del g) | +6.5% | +11.8% | 4th lowest of 15 |
| Hurdle (Req g minus delivered) | +0.3 pp | +1.3 pp | 7th least demanding of 15 |
| ROIC minus cost of capital | -3.1 pp | -3.6 pp | 10th highest of 20 |
| EV / EBITDA | 8.2× | 10.7× | 5th cheapest of 14 |
| Net debt / EBITDA | 6.7× | 1.7× | 3rd most indebted of 15 |
| Bond spread | 377 bp | n/a | — |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Clariane CLARI.PA | France | $1.32B | -20% | +1% | 6% | 8.2× | 6.8% | +6.5% |
| Lumexa Imaging LMRI | United States | $1.35B | +89% | +8% | 2% | 16.0× | n/a | n/a |
| Diagnostyka DIA.WA | Poland | $1.28B | -6% | +19% | 15% | 19.5× | 7.3% | +18.9% |
| Ping An Healthcare and Technology 1833.HK | Hong Kong | $1.36B | -47% | +8% | 3% | 33.5× | 3.5% | -5.1% |
| Pennant PNTG | United States | $1.26B | +1% | +39% | 6% | 23.7× | 20.7% | +19.4% |
| OPKO Health OPK | United States | $1.25B | +37% | -22% | -29% | n/a | n/a | n/a |
| Metropolis Healthcare METROPOLIS.NS | India | $1.25B | +11% | +20% | 18% | 44.5× | 32.4% | +10.5% |
| U.S. Physical Therapy USPH | United States | $1.42B | +53% | +10% | 10% | 29.4× | 18.8% | +13.0% |
| H.U.Group 4544.T | Japan | $1.44B | +24% | +1% | 3% | 39.9× | 9.7% | +2.1% |
| Nutex Health NUTX | United States | $1.19B | +42% | -19% | 39% | 6.5× | -18.0% | +253.5% |
| Teladoc Health TDOC | United States | $1.47B | +24% | -2% | -5% | n/a | -6.4% | +18.3% |
| GoodRx GDRX | United States | $1.15B | +33% | -2% | 12% | 10.6× | 6.3% | +7.7% |
| agilon health AGL | United States | $1.52B | +12% | +2% | -2% | 34.1× | n/a | n/a |
| GeneDx WGS | United States | $1.56B | +16% | +15% | -14% | 54.2× | n/a | n/a |
| Ambea AMBEA.ST | Sweden | $1.59B | +28% | +11% | 9% | 15.2× | 1.1% | +7.7% |
| Sonida Senior Living SNDA | United States | $1.59B | -11% | +70% | -8% | n/a | n/a | n/a |
| Personalis PSNL | United States | $1.62B | +88% | +17% | -157% | n/a | n/a | n/a |
| Vijaya Diagnostic Centre VIJAYA.NS | India | $1.69B | +18% | +24% | 32% | 63.0× | 40.4% | +16.7% |
| Dian Diagnostics 300244.SZ | China | $1.70B | +1% | -5% | 9% | 21.8× | 0.3% | -1.1% |
| Novogene 688315.SS | China | $1.01B | +13% | +6% | 7% | 44.8× | 13.9% | +8.2% |
| AdaptHealth AHCO | United States | $1.01B | -30% | -3% | 3% | n/a | 16.8% | +25.2% |
Clariane has 6 bonds outstanding with $3.02B face value. The agencies rate it B+; its bonds trade like B+. Weighted yield 6.95%, a spread of 377 bp over government bonds.